2023
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
John T, Grohé C, Goldman J, Shepherd F, de Marinis F, Kato T, Wang Q, Su W, Choi J, Sriuranpong V, Melotti B, Fidler M, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu Y, Tsuboi M, Herbst R, Majem M. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. Journal Of Thoracic Oncology 2023, 18: 1209-1221. PMID: 37236398, DOI: 10.1016/j.jtho.2023.05.015.Peer-Reviewed Original ResearchConceptsThree-year safetyAdverse eventsAdjuvant osimertinibStage IBWeek 12Treatment completionCommon adverse eventsMost adverse eventsResected stage IBSignificant efficacy benefitDisease-free survivalNew safety signalsSF-36 surveyHealth-related qualityInterstitial lung diseaseMental component summaryTotal exposure durationADAURA trialWeek 24Component summaryEfficacy benefitsOsimertinib treatmentSF-36Lung diseaseSafety signals
2006
Independent review of fatal interstitial lung disease (ILD) in TRIBUTE: paclitaxel + carboplatin ± erlotinib in advanced non-small cell lung cancer (NSCLC)
Gandara D, Yoneda K, Shelton D, Beckett L, Ramies D, Bloss J, Herbst R. Independent review of fatal interstitial lung disease (ILD) in TRIBUTE: paclitaxel + carboplatin ± erlotinib in advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2006, 24: 7071-7071. DOI: 10.1200/jco.2006.24.18_suppl.7071.Peer-Reviewed Original ResearchNon-small cell lung cancerInterstitial lung diseaseFatal interstitial lung diseaseRisk of ILDConcurrent illnessStudy armsEGFR-TKIILD casesRisk factorsProgressive non-small cell lung cancerAdvanced non-small cell lung cancerIncidence of ILDEGFR tyrosine kinase inhibitor therapyTyrosine kinase inhibitor therapyCell lung cancerKinase inhibitor therapyIndependent blinded assessmentConcurrent chemotherapyErlotinib armInhibitor therapyMedical oncologistsSerious complicationsOverall incidenceAsian patientsLung disease
2004
EGFR inhibition in NSCLC: the emerging role of cetuximab.
Herbst RS. EGFR inhibition in NSCLC: the emerging role of cetuximab. Journal Of The National Comprehensive Cancer Network 2004, 2 Suppl 2: s41-51. PMID: 19780245.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsCell lung cancerTyrosine kinase inhibitorsLung cancerReceptor inhibitorsKinase inhibitorsAdvanced non-small cell lung cancerMonoclonal antibodiesEpidermal growth factor receptor expressionChemotherapy-related toxicityGrowth factor receptor expressionGrowth factor receptor inhibitionRole of cetuximabPhase II trialInterstitial lung diseaseEpidermal growth factor receptor inhibitionOverall response rateFactor receptor expressionModerate rashII trialUntreated patientsHypersensitivity reactionsLung disease